Located in London's rapidly growing Knowledge Quarter, GSK's hub will utilize biomedical data, AI methods and advanced computing platforms to unlock genetic and clinical data with increased precision and scale. The GSK AI hub, once fully operational, will be home to its U.K.-based AI team, including GSK AI Fellows, a new professional training program and now scientists from NVIDIA.
"Because of the massive size of the datasets we use for drug discovery, we need to push the boundaries of hardware and develop new machine learning software", stated Dr. Kim Branson, senior vice president and global head of AI and ML at GSK. "We're building new algorithms and approaches in addition to bringing together the best minds at the intersection of medicine, genetics and artificial intelligence in the U.K.'s rich ecosystem. This new partnership with NVIDIA will also contribute additional computational power and state-of-the-art AI technology."
NVIDIA will contribute its deep expertise in GPU optimization and high-performance computational pipeline development, including NVIDIA Clara Discovery, a new collection of optimized computational drug discovery applications and frameworks. In addition to its investment in NVIDIA DGX A100 systems, GSK will have access to NVIDIA's Cambridge-1, the United Kingdom's most powerful AI supercomputer.
"GSK and NVIDIA together will help push the boundaries of what AI can do and put vast data sources to work to advance the discovery of new medicines and vaccines", stated Kimberly Powell, vice president of health care at NVIDIA. "GSK is leading the industry in defining the next generation of data-driven drug discovery by harnessing genetic and clinical data to bring more precision to research and medicine."